Current projects of the laboratory

• Targeted inhibition of the metastatic process by biodegradable polymeric conjugates simultaneously carrying matrix metalloproteinase inhibitors and cytostatic drugs

•  Drug delivery system based on tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance with a combination of unique properties based on MDR inhibition, stimuli sensitiveness (pH sensitive activation of drug), improved pharmacokinetics and increased uptake into the cells

• Synergistic therapy of tumors with the use of polymeric prodrugs combining immunomodulation and blockade of immune checkpoint inhibitors thus acting as an endogenous vaccine

• Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation towards induction of anticancer immune response

• Elucidation of the extremely strong sensitization to LPS mediated shock and mortality by IL-2/anti-IL-2 mAb immunocomplexes with high selectivity for CD25⁺ cells

Polymeric prodrugs
combining immunomodulation
and blockade of immune checkpoint inhibitors acting as an
endogenous vaccine
for synergistic therapy
of tumors

Targeted therapy of chemoresistant tumors with micellar drug carrier operating via three synergic mechanisms